Giuseppe Tonini
Full Professor of Medical Oncology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (46)
Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7
Year:
2026
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes medications: 17.5 months (95%CI: 14.2 – 26.6; 77 events). B) Progression Free Survival NSCLC matched cohort; patients on any diabetes medication: 7.9 months (95%CI: 5.4 – 10.8; 113 events), patients not receiving diabetes medications: 10.1 months (95%CI: 7.7 – 13.8; 99 events). C) Overall Survival Melanoma matched cohort; patients on any diabetes medication: 22.9 months (95%CI: 12.0 – NR; 25 events), patients not receiving diabetes medications: NR months (95%CI: 28.8 – NR; 52 events). D) Progression Free Survival Melanoma matched cohort; patients on any diabetes medication: 11.4 months (95%CI: 4.9 – 23.4; 37 events), patients not receiving diabetes medications: 13.8 months (95%CI: 8.7 – 26.0; 77 events). NR: not reached; PSM: propensity score matching.
Year:
2025
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).
Year:
2025
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.
Year:
2025
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving diabetes medications: 18.9 months (95%CI: 15.9-21.6; 684 events), patients on other diabetes medications/insulin therapy only: 19.3 months (95%CI: 11.6-22.9; 48 events), patients on metformin: 12.3 months (95%CI: 9.8-15.9; 100 events). B) Progression Free Survival whole cohort; patients not receiving diabetes medications: 8.2 months (95%CI: 7.1-9.4; 872 events), patients on other diabetes medications/insulin therapy only: 10.7 months (95%CI: 6.7-11.6; 61 events), patients on metformin: 7.9 months (95%CI: 5.1-10.1; 124 events).
Year:
2025
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 months (95%CI: 10.0 – 18.9; 69 events), patients not receiving diabetes medications: 18.9 months (95%CI: 15.9 – 21.5; 684 events). B) Progression Free Survival whole cohort; patients on more than one diabetes medications: 7.9 months (95%CI: 6.2-11.4; 101 events), patients on one medication: 8.4 months (95%CI: 4.9 – 11.9; 84 events), patients not receiving diabetes medications: 8.2 months (95%CI: 7.1 – 9.4; 872 events). Polypharmacy: more than one diabetes medication.
Year:
2025
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
NSCLC cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:1, caliper 0.1).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (37)
Fabio Puglisi
Head of the Unit of Medical Oncology and Cancer Prevention
-
Valentina Guarneri
Associate Professor
University of Padova
Maurizio Simmaco
Full Professor Molecular Biology - Director Diparmet Diagnostic sciences
Sapienza University of Rome
Umberto Malapelle
-
Edoardo Crimini
Medical Oncologist
European Institute of Oncology
Marco Gaetano Tucci
Associate Professor
University of Bari
David J. Pinato
Imperial College London
Bruno Vincenzi
Professor of Medical Oncology
Università Campus Bio-Medico
Giuseppe Giannini
Head, Unit of Advanced Molecular Diagnostic in Oncology
Sapienza University
Maria Grazia Vitale
Fondazione IRCCS Istituto Nazionale dei Tumori
Armando Orlandi
Università Cattolica del Sacro Cuore
Lucia Del Mastro
dirigente medico
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro
Sebastiano Buti
Ricercatore a contratto tipo B
University of Parma
Andrea DeCensi
Director
Champalimaud Foundation
Lorenzo Nibid
Campus Bio Medico University Hospital
Giancarlo Pruneri
University of Milan
Marco Ferrari
Associate Professor
University of Padova
Alessio Cortellini
Imperial College London
Maria Giuseppa Vitale
-
Giuseppe Curigliano
European Institute of Oncology
Lidia Strigari
Head of Department
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Alberto Zambelli
Associate Professor
University of Milano-Bicocca
Paolo Marchetti
Sapienza University of Rome
SIMONA PISEGNA
Sapienza University of Rome
Michele Ghidini
Docenti di ruolo di IIa fascia
University of Insubria
Francesco Pantano
National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)
Ministero dell’Istruzione, dell’Università e della Ricerca
Antonio Avallone
Chief of DH Chemotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Melissa Bersanelli
Adjunct Professor in Medical Oncology
University of Parma
olga nigro
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessandro Russo
Humanitas University
MICHELE DE TURSI
ASSOCIATE PROFESSOR
University "G. d'Annunzio"
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
PIERFRANCO CONTE
Professore di 1^ fascia
University of Padova
Chiara Cremolini
University Hospital of Pisa
Giuseppe Perrone
Università Campus Bio-Medico di Roma
Antonio D'Alessio
King's College Hospital
Make your next move.
Prepare your application
Review drafts before you send them.